期刊文献+

脂质制剂体外动态肠吸收模型的建立及评价 被引量:3

Establishment and evaluation of a dynamic in vitro intestinal absorption model of lipid formulations
原文传递
导出
摘要 根据脂质制剂肠消化吸收的特性,本文在体外脂解模型基础上,引入肠吸收评价方法,建立了一种用于筛选评价脂质制剂的新型体外动态肠吸收模型,包括肠消化和肠组织培养两大体系。探究模型重要参数(Ca2+、葡萄糖、K+)的影响,发现Ca2+浓度的增加能显著增强脂质制剂的肠消化;葡萄糖浓度的递增能显著减慢肠组织活性衰减;K+虽能维持肠组织的活性,但其浓度变化对肠组织活性衰减并无显著性影响;最终选择Ca2+10 mmol.L-1、葡萄糖15 mmol.L?1和K+5.5 mmol.L-1为模型参数。利用该模型评价TypeⅠ脂质制剂得到的体外吸收曲线与大鼠体内吸收曲线呈现极显著的点对点相关性(r=0.995 6,P<0.01)。本模型可望应用于脂质制剂的筛选、评价及预测。 A new dynamic in vitro intestinal absorption model for screening and evaluating lipid formulations was established by means of the characteristics of the intestinal digestion and absorption of the lipid formulations.This model was composed of two systems,including intestinal digestion and the intestinal tissue culture,which drew the evaluation method of intestinal absorption into the in vitro lipolysis model.The influence of several important model parameters such as Ca2+,D-glucose,K+ on the two systems of this model has been investigated.The results showed that increasing of Ca2+ concentration could be significantly conductive to intestinal digestion.The increasing of D-glucose concentration could stepped significantly down the decay of the intestinal activity.K+ was able to maintain intestinal activity,but the influence of different concentration levels on the decay of the intestinal activity was of no significant difference.Thus the model parameters were set up as follows: Ca2+ for 10 mmol-L-1,D-glucose for 15 mmol-L-1 and K+ for 5.5 mmol-L-1.Type Ⅰ lipid formulation was evaluated with this model,and there was a significant correlation between the absorption curve in vitro and absorption curve in vivo of rats(r = 0.995 6,P 0.01).These results demonstrated that this model can be an attractive and great potential method for the screening,evaluating and predicting of the lipid formulations.
出处 《药学学报》 CAS CSCD 北大核心 2011年第8期983-989,共7页 Acta Pharmaceutica Sinica
基金 重庆市自然科学基金项目(CSTC2009BB5106) 中央高校基本科研业务费专项资金(XDJK2009C076) 重庆高校优秀成果转化(KJ08B06) 西南大学博士基金项目(SWUB2008032)
关键词 脂质制剂 肠消化 肠组织活性 吸收 体内外相关性 lipid formulation intestinal digestion intestinal activity absorption in vitro-in vivo correlation
  • 相关文献

参考文献4

二级参考文献11

共引文献49

同被引文献28

  • 1张宁,王海学,钱思源.浅谈细胞毒类抗肿瘤药物脂质体制剂的研究思路[J].中国新药杂志,2006,15(21):1805-1807. 被引量:6
  • 2Stella V J, Nti-Addae KW. Prodrug strategies to overcome poor wa- ter solubility[ J]. Adv Drug Deliv Rev, 2007, 59(7) :677-694.
  • 3Yu LX, Amidon GL, Polli JE, et al. Biopharmaceutics classifi- cation system: the scientific basis for biowaiver extensions [ J ]. Pharm Res, 2002,19 (7) :921-925.
  • 4Gifiyar C, Fikstad DT, Tyavanagimatt S. Challenges and oppor- tunities in oral delivery of poorly water-soluble drugs [ J ]. Drug Deliv Techno1,2006,6( 1 ) :57-63.
  • 5Hauss DJ. Oral lipid-based formulations [ J]. Adv Drug Dellv Rev, 2007,59 ( 7 ) :667-676.
  • 6Colin WP. Formulation of poorly water-soluble drugs for oral ad- ministration: physicochemical and physiological issues and the lipid formulation classification system [ J ]. Eur J Pharm, 2006, 29 (3-4) :278-287.
  • 7Pouton CW. Formulation of poorly water soluble drugs for oral ad-ministration: physicochemical issues and the lipid formulation classification system [ J ]. Eur J Pharm, 2006 (29) :278-287.
  • 8Hamberstone A J, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs[ J]. Adv Drug Deliv Rev, 1997, 25:103-108.
  • 9Pouton CW, Porter CJH. Formulatiorl. of lipid-based delivery sys- tems for oral administration: materials, methods and strategies [J]. Adv DrugDeliv Rev, 2008, 60: 625-637.
  • 10Setbia S, Squillante E. Solid dispersion:revival with greater pos- sibilities and application in oral drug delivery[ J]. Crit Rev Ther Drug Carrier Syst, 2003,20 ( 2-3 ) :215-247.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部